535
edits
Changes
no edit summary
The US reported having approximately $128 billion of direct and $47.0 billion of indirect costs billable to arthritis and related rheumatic conditions. In the UK, this number came down to £560 million a year in health care costs.<ref name=”[31]”>Fazal, S.A. et al. (2018). A Clinical Update and Global Economic Burden of Rheumatoid Arthritis. ''Endocrine, Metabolic & Immune disorders - Drug Targets, 18''(2), 98-109. [https://doi.org/10.2174/1871530317666171114122417 ''doi:10.2174/1871530317666171114122417'']</ref>
In 2017, adalimumab (Humira) was at the top of pharmaceutical products by sales worldwide. The drug generated more than 18.4 billion US dollars. Almost twice as much as Rituxan, who took second place with 9.2 billion dollars generated.<ref name=”[33]”>Statista (2018). Top 15 pharmaceutical products by sales worldwide in 2017. Accessed on 7 November 2018, at [https://www.statista.com/statistics/258022/top-10-pharmaceutical-products-by-global-sales-2011/ ''https://www.statista.com/statistics/258022/top-10-pharmaceutical-products-by-global-sales-2011/''].</ref> In 2015, Humira cost costs around $2669 per month in the US and $1362 in the UK.<ref name=”[34]”>Statista (2018). Average prices of Humira in selected countries in 2015. Accessed on 7 November 2018, at [https://www.statista.com/statistics/312014/average-price-of-humira-by-country/ ''https://www.statista.com/statistics/312014/average-price-of-humira-by-country/''].</ref>
== References ==
<references />